QIAGEN NV EO -,01 chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 9.79
Dividend & YieldN/A€ (N/A)
Beta 0.42
Market capitalization 10.61B
Operating cash flow 826.39M
ESG Scores 15.5

Company description

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

Sector: Healthcare - Industry: Diagnostics & Research

Financial Ratios
Quick Ratio1.17
Working Capital0.87
Return On Equity0.17
Debt To Equity0.35
Fixed Asset Ratio0.14
Fixed Interest Cover12.08

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 6.99M 9.25M 8.44M -5.97M
Total Cashflows From Investing Activities -211.36M -222.28M -453.29M -211.7M
Net Borrowings 493.57M -640.16M -59.74M -68.77M
Total Cash From Financing Activities 360.41M -639.08M -74.32M -177.79M
Change To Operating Activities -37.66M 22.81M 74.84M 19.78M
Issuance Of Stock 4.41M 136.81M 7.66M 7.92M
Net Income 190.38M -41.45M 73.64M 537.05M
Change In Cash 501.37M -529.69M -31.23M 282.88M
Effect Of Exchange Rate -7.18M 826k 4.11M -3.62M
Total Cash From Operating Activities 359.5M 330.84M 492.27M 675.99M
Depreciation 189.24M 213.16M 98.39M 101.71M
Change To Account Receivables -41.81M -39.58M -14.71M -7.4M
Other Cashflows From Financing Activities -32.89M -11.28M 55.6M 6.62M
Change To Netincome 22.3M 144.4M 149.54M -137.14M
Capital Expenditures -109.77M -117.95M -79.91M -138.61M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 161.85M 157.45M 139.06M 180.69M
Income Before Tax 225.74M -77.78M 154.93M 651.1M
Net Income 190.38M -41.45M 73.64M 537.05M
Selling General Administrative 496.85M 504.17M 544.31M 600.92M
Gross Profit 1.06B 1.08B 1.29B 1.51B
Ebit 304.84M 287.74M 525.59M 644.43M
Operating Income 304.84M 287.74M 525.59M 644.43M
Interest Expense -67.29M -74.19M -70.4M -59.59M
Income Tax Expense 35.36M -36.32M 81.29M 114.05M
Total Revenue 1.5B 1.53B 1.87B 2.25B
Cost Of Revenue 442.55M 449.65M 579.37M 738.08M
Total Other Income ExpenseNet -79.11M -365.51M -370.67M 6.67M
Net Income From Continuing Ops 190.38M -41.45M 73.64M 537.05M
Net Income Applicable To Common Shares 190.38M -41.45M 73.64M 537.05M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 3.11B 2.7B 3.45B 3.35B
Total Stockholder Equity 2.63B 2.54B 2.48B 2.86B
Other Current Liabilities 217.2M 446.03M 224.64M 484.84M
Total Assets 5.75B 5.24B 5.93B 6.21B
Common Stock 2.7M 2.7M 2.7M 2.7M
Other Current Assets 152.54M 136.64M 101.36M 207.4M
Retained Earnings 1.38B 1.18B 998.13M 1.49B
Treasury Stock -489.55M -421.58M -357.9M -512.49M
Cash 1.16B 623.65M 597M 879.88M
Total Current Liabilities 972.19M 951.35M 570.89M 1.63B
Other Stockholder Equity -310.64M -309.62M -239.6M -322.76M
Property, Plant, and Equipment 511.66M 512.55M 528.56M 590.77M
Total Current Assets 2.16B 1.57B 1.6B 2.07B
Net Tangible Assets 51.39M -236.35M -764.28M -291.81M
Net Receivables 397.68M 469.74M 455.48M 446.75M
Accounts Payable 69.42M 84.77M 118.15M 101.22M


Insider Transactions

Here are the insider transactions of stock shares related to QIAGEN NV EO -,01:

Filer Name Transaction Text Ownership Date Filer Relation Shares
NO DATA

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to QIAGEN NV EO -,01. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on QIAGEN NV EO -,01

Here is the result of two systematic investment strategies applied to QIAGEN NV EO -,01. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on QIAGEN NV EO -,01

The following chart shows the equity curve of the two systematic investment strategies applied to QIAGEN NV EO -,01:

QIAGEN NV EO -,01 automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 26.26% on the backtest period.

Performance at glance

Performance

26.26 %

Latent gain

401.29 €

Invested capital

1528.17 €

Annualized return

6.37 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on QIAGEN NV EO -,01

This is the result of two momentum investment strategies applied to QIAGEN NV EO -,01. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on QIAGEN NV EO -,01

The following chart shows all the entries opened by the momentum investment system on QIAGEN NV EO -,01:

QIAGEN NV EO -,01 momentum entries
  • The first momentum investment strategy would give 38.8% of return on QIAGEN NV EO -,01. That represents 1631.11€ of latent gain with 4204.33€ of employed capital.
  • The second momentum investment strategy would give 33.78% of return on QIAGEN NV EO -,01. That represents 1009.95€ of latent gain with 2990.15€ of employed capital.
Performance at glance (1Q Momentum)

Performance

38.8 %

Latent gain

1631.11 €

Invested capital

4204.33 €

Annualized return

7.55 %
Performance at glance (2Q Momentum)

Performance

33.78 %

Latent gain

1009.95 €

Invested capital

2990.15 €

Annualized return

9.28 %

Momentum equity curve on QIAGEN NV EO -,01

The following chart shows the equity curve of the two momentum strategies applied to QIAGEN NV EO -,01:

QIAGEN NV EO -,01 momentum equity

Note: the dividends potentially given by QIAGEN NV EO -,01 are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on QIAGEN NV EO -,01

The following chart shows the employed capital evolution of the two momentum strategies on QIAGEN NV EO -,01 since the beginning:

QIAGEN NV EO -,01

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250€, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000€.


Buy the dip strategy result on QIAGEN NV EO -,01

Buy the dip entry openings on QIAGEN NV EO -,01

QIAGEN NV EO -,01

The performance achieved by the robo-advisor on QIAGEN NV EO -,01 is 16.01%. That represents 155.88$ of latent gain with 973.56€ of employed capital. The following chart shows QIAGEN NV EO -,01 stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of QIAGEN NV EO -,01, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

16.01 %

Latent gain

155.88 €

Invested capital

973.56 €

Annualized return

7.55 %

Equity curve of the strategy applied to QIAGEN NV EO -,01

The following chart shows the result of the investment strategy applied to QIAGEN NV EO -,01:

QIAGEN NV EO -,01

Note: the dividends potentially given by QIAGEN NV EO -,01 are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on QIAGEN NV EO -,01

The following chart shows the employed capital evolution since the beginning of the investment strategy on QIAGEN NV EO -,01:

QIAGEN NV EO -,01

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on QIAGEN NV EO -,01

In this section, I will compare the three previous investment strategies applied to QIAGEN NV EO -,01.

Equity curve comparison on QIAGEN NV EO -,01

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

QIAGEN NV EO -,01 investment strategy comparison

Employed capital comparison on QIAGEN NV EO -,01

QIAGEN NV EO -,01 investment comparison

Performance comparison on QIAGEN NV EO -,01

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 26.26% 401.29€ 1528.17€ 6.37%
Momentum 1 quarter 38.8% 1631.11€ 4204.33€ 10.0%
Momentum 2 quarters 33.78% 1009.95€ 2990.15€ 9.28%
Non-directional 16.01% 155.88€ 973.56€ 7.55%
Annualized return comparison

Automatic investment

6.37 %

Momentum 1Q

9.28 %

Momentum 2Q

9.28 %

Non-directional

7.55 %

Correlated stocks

Here are the most positively and negatively correlated stocks with QIAGEN NV EO -,01:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between QIAGEN NV EO -,01 and the other stocks. There may be false positives or some missing correlated stocks. If the price of QIAGEN NV EO -,01 does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name QIAGEN NV EO -,01
Country Netherlands
City Venlo
Address Hulsterweg 82
Phone 31 77 355 6600
Website www.qiagen.com
FullTime employees 6200
Industry Diagnostics & Research
Sector Healthcare
Exchange XETRA
Ticker QIA.XETRA
Market www.xetra.com

QIAGEN NV EO -,01 ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 1.6
Peer Environment Performance 2.0330864197531
Environment Percentile unknown
Palm Oil no
Nuclear no
Fur Leather no
GMO no
Coal no
Pesticides no
Animal Testing yes

Social scores

Social ESG Factors Scores
Social Score 6.5
Peer Social Performance 14.299012345679
Social Percentile unknown
Highest Controversy 2
Peer Highest Controversy Performance 1.8780487804878
Adult no
Gambling no
Alcoholic no
Tobacco no
Catholic yes
Controversial Weapons no
Small Arms no
Military Contract no
Peer Count yes

Related Controversy: Business Ethics Incidents


Governance scores

Governance ESG Factors Scores
Governance Score 7.4
Peer Governance Performance 8.8141975308642
Governance Percentile unknown

ESG at glance
Total ESG Scores: 15.5
Environment Score: 1.6
Social Score: 6.5
Governance Score: 7.4

ESG Performance: UNDER_PERF

Peer Group: Pharmaceuticals

Peer Esg Score Performance: 25.306097560976

Rating Year: 2022

Rating Month: 8

Max Age: 86400

Percentile: 11